{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T10:46:12Z","timestamp":1781174772101,"version":"3.54.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jiac.2023.07.012","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T13:12:49Z","timestamp":1690290769000},"page":"1097-1102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["A single-center, person-month-based analysis of the risk of developing Pneumocystis pneumonia (PCP) in immunosuppressed non-HIV patients: Preventive effects of trimethoprim-sulfamethoxazole"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5977-8795","authenticated-orcid":false,"given":"Kohei","family":"Miyake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuji","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3439-8569","authenticated-orcid":false,"given":"Yasuharu","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2023.07.012_bib1","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-4-42","article-title":"Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention","volume":"4","author":"Sowden","year":"2004","journal-title":"BMC Infect Dis"},{"issue":"9","key":"10.1016\/j.jiac.2023.07.012_bib2","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3899\/jrheum.141510","article-title":"Pneumocystis jirovecii pneumonia in Japanese patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a pooled analysis of 3 agents","volume":"42","author":"Tanaka","year":"2015","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.jiac.2023.07.012_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/PL00021707","article-title":"Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy","volume":"15","author":"Ogawa","year":"2005","journal-title":"Mod Rheumatol"},{"issue":"18","key":"10.1016\/j.jiac.2023.07.012_bib4","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1056\/NEJMc070728","article-title":"Pneumocystis pneumonia associated with infliximab in Japan","volume":"357","author":"Harigai","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jiac.2023.07.012_bib5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/annrheumdis-2015-207511","article-title":"The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression","volume":"75","author":"Atsumi","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jiac.2023.07.012_bib6","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3899\/jrheum.090843","article-title":"A survey of rheumatologists' practice for prescribing pneumocystis prophylaxis","volume":"37","author":"Cettomai","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jiac.2023.07.012_bib7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0140-6736(90)92008-6","article-title":"Detection of Pneumocystis carinii with DNA amplification","volume":"336","author":"Wakefield","year":"1990","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jiac.2023.07.012_bib8","doi-asserted-by":"crossref","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"3","key":"10.1016\/j.jiac.2023.07.012_bib9","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jiac.2023.07.012_bib10","article-title":"Intermittent courses of corticosteroids also present a risk for pneumocystis pneumonia in non-HIV patients","volume":"2016","author":"Calero-Bernal","year":"2016","journal-title":"Can Respir J J Can Thorac Soc"},{"issue":"11","key":"10.1016\/j.jiac.2023.07.012_bib11","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JOP.18.00366","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update summary","volume":"14","author":"Taplitz","year":"2018","journal-title":"J Oncol Pract"},{"issue":"6","key":"10.1016\/j.jiac.2023.07.012_bib12","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00277-021-04452-9","article-title":"Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical","volume":"100","author":"Annika","year":"2021","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.jiac.2023.07.012_bib15","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","article-title":"Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jiac.2023.07.012_bib16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/acr.21812","article-title":"Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis","volume":"65","author":"Widdifield","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jiac.2023.07.012_bib17","first-page":"1","article-title":"Treatment for rheumatoid arthritisand the risk of hospitalization for pneumonia","author":"Frederick Wolfe","year":"2006","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jiac.2023.07.012_bib18","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/rheumatology\/kep101","article-title":"Methotrexate, rheumatoid arthritis and infection risk\u2014what is the evidence?","volume":"48","author":"McLean-Tooke","year":"2009","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.jiac.2023.07.012_bib19","first-page":"387","article-title":"The Journal of Rheumatology the risk of hospitalized infection in patients with rheumatoid arthritis","volume":"35","author":"AL","year":"2008","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.jiac.2023.07.012_bib20","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3899\/jrheum.140853","article-title":"Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy","volume":"42","author":"Aaltonen","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jiac.2023.07.012_bib21","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/6730812","article-title":"Incidence and risk factors for infections requiring hospitalization, including pneumocystis pneumonia, in Japanese patients with rheumatoid arthritis","volume":"2017","author":"Hashimoto","year":"2017","journal-title":"Int J Rheumatol"},{"issue":"5","key":"10.1016\/j.jiac.2023.07.012_bib22","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3109\/s10165-006-0502-6","article-title":"Evaluation of Pneumocystis pneumonia infection risk factors in patients with connective tissue disease","volume":"16","author":"Iikuni","year":"2006","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jiac.2023.07.012_bib23","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3109\/s10165-012-0615-z","article-title":"Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients","volume":"22","author":"Tanaka","year":"2012","journal-title":"Mod Rheumatol"},{"issue":"6","key":"10.1016\/j.jiac.2023.07.012_bib24","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3109\/s10165-012-0796-5","article-title":"Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab. Modern rheumatology","volume":"23","author":"Watanabe","year":"2013","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.jiac.2023.07.012_bib25","article-title":"Risk factors and clinical characteristics of Pneumocystis jirovecii pneumonia in lung cancer","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jiac.2023.07.012_bib26","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1996-6","article-title":"Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids - clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole","volume":"21","author":"Park","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.jiac.2023.07.012_bib27","article-title":"Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients","volume":"2014","author":"Stern","year":"2014","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X23001745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X23001745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:06:36Z","timestamp":1761159996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X23001745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1341321X23001745"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2023.07.012","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A single-center, person-month-based analysis of the risk of developing Pneumocystis pneumonia (PCP) in immunosuppressed non-HIV patients: Preventive effects of trimethoprim-sulfamethoxazole","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2023.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}